Evolving Oncology Diagnostics

Just across the United States, we shall see 19 million new cases by 2024 and spend of $156 billion by 2020 – on cancer alone. Cancer is a devastating disease, not just for patients and families, but also for healthcare systems globally. From academic research institutes to physicians and hospitals to medical device makers, medical imaging vendors & health IT vendors, all involved stakeholders are trying to improve cancer care, to ultimately enable early diagnosis, prevent complications, and ensure longer remission-free days.

Diagnostics plays an important role in detecting cancer. Personalized medicine continues to be a driver of new diagnostics to characterize the properties of an individual’s cancer. As a result there is an increased focus on development of noninvasive liquid biopsy companion diagnostic tests that would aid in choosing the best treatment for an individual. Liquid biopsy has triggered market consolidation as participants fill in the gaps in their technology set, skill set, or expertise through acquisitions of specialized laboratories.

This bundle is designed to understand the oncology diagnostics space across the US and Western Europe, along with precision medicine growth opportunities across the board.